Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

Biden to order analysis of pharma supply chain

By Chris Newmarker | February 24, 2021

President Joe Biden

President Joe Biden [Image courtesy of the White House]

President Joe Biden today plans to sign an executive order for a comprehensive review of U.S. supply chains for active pharmaceutical ingredients (APIs) and other products.

The order includes an immediate 100-day review across federal agencies to address vulnerabilities in the supply chains related to APIs and three other key products — critical minerals, semiconductors and advanced packaging, and large-capacity batteries.

There are also plans for a more in-depth one-year review of a broader set of U.S. supply chains, including those supporting defense, public health and biological preparedness, information and communications technology (ICT), the energy sector, transportation and, and agricultural commodities and food production.

A White House fact sheet related to the order notes that more than 70% of API production facilitators supplying the U.S. have moved offshore over the years.

The COVID-19 pandemic quickly caused a painful awareness of how much API production had moved outside the country. Former President Donald Trump in August 2020 signed an executive order meant to encourage the reshoring of pharmaceutical manufacturing to the U.S. Trump’s order included “buy American” provisions for U.S. government agencies’ procurement of essential medicines and reduced regulatory provisions.

The White House fact sheet says Biden’s new order will “complement the ongoing work to secure supply chains needed to combat the COVID-19 pandemic.”

Tell Us What You Think! Cancel reply

Related Articles Read More >

vaccine vial
How end-to-end visibility and machine learning can safeguard the vaccine supply chain
Johnson & Johnson
Johnson & Johnson COVID-19 vaccine shipments plunge
Emergent Biosolutions
Emergent reportedly had serious problems at Baltimore vaccine plant
Canadian flag Canada Sanofi influenza vaccine
Sanofi to spend nearly $700M on new flu vaccine plant in Canada

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards